In a groundbreaking development in the field of obesity and cardiovascular disease treatment, the FDA has approved ‘Wegovy’ for use as a heart disease prevention medication. Wegovy, an injectable semaglutide manufactured by Novo Nordisk, is now indicated to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are overweight or obese.
This approval marks a significant milestone as Wegovy is the first weight-loss medication to be approved for preventing life-threatening cardiovascular events. The decision came after a large double-blind trial with 17,600 participants, which showed a notable reduction in cardiovascular death, heart attack, and stroke for those taking Wegovy.
Experts such as Brooke Boyarsky Pratt and Dr. Darren McGuire have lauded the FDA’s decision, hailing it as a landmark in the treatment of obesity and cardiovascular disease. McGuire estimates that approximately one in five U.S. adults could benefit from treatment with semaglutide.
Furthermore, other medications in the same class as Wegovy are currently being developed and tested for cardiovascular efficacy. Patients are advised to discuss the potential benefits and side effects of Wegovy with their healthcare provider.
Despite the significant impact of this approval, Novo Nordisk did not provide additional comments to Fox News Digital at the time of reporting. As research and development in this area continue to advance, the approval of Wegovy signifies a major step forward in the fight against obesity-related cardiovascular risks.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”